newsfilter
← Latest News
PR Newswire·

BiondVax's Strategic Research Collaboration with Max Planck and UMG: Significant progress towards development of innovative nanosized antibodies (NanoAbs) for therapeutic indications in addition to COVID-19

JERUSALEM, Sept. 20, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), which focuses on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today p